The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target

被引:28
作者
Chu, Jin
Pratico, Domenico
机构
[1] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA
[2] Temple Univ, Sch Med, Ctr Translat Med, Philadelphia, PA 19140 USA
关键词
Alzheimer's disease; 5-lipoxygenase; Amyloid beta; gamma-Secretase; gamma-Secretase activating protein; LEUKOTRIENE RECEPTOR 1; ACTIVATING PROTEIN; MOUSE MODEL; CYSTEINYL-LEUKOTRIENE; IN-VITRO; DISEASE; TAU; INVOLVEMENT; EXPRESSION; MEMORY;
D O I
10.1016/j.brainresbull.2016.03.010
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer's disease (AD) is an age-related, neurodegenerative disorder characterized by cognitive impairment with memory loss, extracellular amyloid beta (A beta) peptides aggregation, and intracellular hyper-phosphorylated tau neurofibrillary tangles (NFT) accumulation. Although the 5-lipoxygenase (5LO) protein enzyme is well known as an important modulators of oxidation and inflammation, recent work has highlighted the new hypothesis that this pathway may play a direct role in AD pathogenesis. In this review article, we will discuss how the 5LO via the gamma-secretase influences A beta peptides formation, and other molecular pathologies including neuroinflammation, synaptic integrity, and cognitive functions, and provide an assessment of how targeting this protein could lead to novel therapeutics for AD and other related neurodegenerative disorders. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:207 / 212
页数:6
相关论文
共 50 条
  • [21] 5-Lipoxygenase as an emerging target against age-related brain disorders
    Yan, Mengdie
    Zhang, Siran
    Li, Chengtan
    Liu, Yanyan
    Zhao, Jianbo
    Wang, Yanfang
    Yang, Yi
    Zhang, Lihui
    AGEING RESEARCH REVIEWS, 2021, 69
  • [22] Presenilin and γ-Secretase Activity: A Viable Therapeutic Target for Alzheimer's Disease?
    Yan, Run
    McCarthy, Justin V.
    CURRENT SIGNAL TRANSDUCTION THERAPY, 2010, 5 (02) : 128 - 140
  • [23] SAR-studies of γ-secretase modulators with PPARγ-agonistic and 5-lipoxygenase-inhibitory activity for Alzheimer's disease
    Flesch, Daniel
    Ness, Julia
    Lamers, Christina
    Dehm, Friederike
    Popella, Sven
    Steri, Ramona
    Ogorek, Isabella
    Hieke, Martina
    Dannhardt, Gerd
    Werz, Oliver
    Weggen, Sascha
    Schubert-Zsilavecz, Manfred
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (04) : 841 - 846
  • [24] Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model
    Chu, Jin
    Pratico, Domenico
    JOURNAL OF NEUROINFLAMMATION, 2012, 9
  • [25] Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an Alzheimer's Disease Transgenic Mouse Model Involvement of γ-Secretase
    Chu, Jin
    Pratico, Domenico
    AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (04) : 1762 - 1769
  • [26] β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease
    Menting, Kelly Willemijn
    Claassen, Jurgen A. H. R.
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6 : 1 - 20
  • [27] Therapeutic options for 5-lipoxygenase inhibitors
    Werz, Oliver
    Steinhilber, Dieter
    PHARMACOLOGY & THERAPEUTICS, 2006, 112 (03) : 701 - 718
  • [28] 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease
    Chen, Fang
    Ghosh, Arijit
    Lin, Jingran
    Zhang, Chunteng
    Pan, Yining
    Thakur, Abhimanyu
    Singh, Kunal
    Hong, Hao
    Tang, Susu
    BRAIN BEHAVIOR AND IMMUNITY, 2020, 88 : 844 - 855
  • [29] Novel 5-lipoxygenase isoforms affect the biosynthesis of 5-lipoxygenase products
    Boudreau, Luc H.
    Bertin, Jonathan
    Robichaud, Philippe P.
    Laflamme, Mark
    Ouellette, Rodney J.
    Flamand, Nicolas
    Surette, Marc E.
    FASEB JOURNAL, 2011, 25 (03) : 1097 - 1105
  • [30] Microglia in Alzheimer's Disease: A Target for Therapeutic Intervention
    Zhang, Guimei
    Wang, Zicheng
    Hu, Huiling
    Zhao, Meng
    Sun, Li
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2021, 15